Nascent Stem Cell Company Raises Ethical and Medical Issues
By Bernadette Tansey,
San Francisco Chronicle
| 10. 29. 2007
A San Carlos startup is offering to create "personalized" stem cells from the spare embryos of fertility clinic clients on the chance that the cells, frozen and stored away, may some day help a family member benefit from medical breakthroughs.
The novel business plan of StemLifeLine Inc. - which started promoting its service to fertility patients earlier this year as "insurance for the future" - set off a flash fire of protest from stem cell research opponents and supporters alike.
The outcry from anti-abortion groups wasn't surprising. StemLifeLine derives stem cells from very early stage human embryos, which are destroyed in the process. Opponents of the research see this as the moral equivalent of killing a child. This belief is the basis of the Bush administration's limits on federal funding of embryonic stem cell research.
But some of the most fervent denunciations of StemLifeLine came from vigorous supporters of embryonic stem cell research. Two Stanford University critics aired their complaints in newspaper editorial pages. A prominent Stanford ethicist challenged UC San Francisco scientists who are advisers of the company to...
Related Articles
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...
By Darren Incorvaia, Fierce Biotech | 03.11.2026
A new method for safely inserting large chunks of DNA into genomes has now measured up in mice, potentially paving the way for the next generation of gene editing medicines.
The approach, which is described in a Nature paper...
By Carolyn Riley Chapman and Nirvan Bhatia, Hastings Bioethics Forum | 03.12.2026
Last year, researchers saved an infant named KJ from a life-threatening rare metabolic disorder using a customized gene editing therapy. This was the first time that an individualized gene therapy was used to treat a human patient, and it has...
By Ryan Cross, Endpoints News | 03.24.2026
Cathy Tie has an audacity more typical of a tech startup founder than a biotech executive. She dropped out of college to start a genetic screening company and later founded a telemedicine startup. The 29-year-old has been on two Forbes...